Bellbrook Labs
Bellbrook Labs is a privately held Madison, Wisconsin-based biochemical assay company founded in 2005 that develops and sells Transcreener, AptaFluor, Heliscreener, and Enzolution high-throughput screening assay kits, recombinant enzymes, and contract profiling services for enzyme-targeted drug discovery by pharmaceutical, biotech, academic, and CRO customers.
- Company typePrivate
- Founded2005
- HeadquartersMadison, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bellbrook Labs does
Bellbrook Labs is a privately held biochemical assay company founded in 2005 and headquartered in Madison, Wisconsin. The company develops and sells high-throughput screening (HTS) assay platforms used by pharmaceutical, biotechnology, academic, and contract research organizations for enzyme-targeted drug discovery. Its technology portfolio centers on direct nucleotide detection via the Transcreener platform — covering kinases, ATPases, GTPases, phosphodiesterases, glycosyltransferases, and exonucleases — and is extended through AptaFluor methyltransferase assays, Heliscreener helicase assays, the Enzolution complete assay systems, and a catalog of HTS-ready recombinant human enzymes.
Bellbrook Labs monetizes through three channels: (1) catalog sales of assay kits and recombinant enzymes via direct e-commerce, an inside sales team, and an international distributor network; (2) fee-for-service scientific offerings including assay development, hit validation, ATPase/cGAS-STING/GTPase/helicase profiling, and lead discovery; and (3) free evaluation kits and a webinar/conference-driven content marketing motion. The mix-and-read, direct-detection format is positioned as a robust, low-interference alternative to luciferase-coupled assays, with validated performance in 384- and 1536-well automated formats.
The company operates with 11-50 employees, is founder-led (Robert Lowery serves as co-founder, president, and CEO), and shows no institutional venture capital backing in its disclosed funding record — only a 2012 round and a 2017 NIH NIGMS SBIR Phase I grant of $288,000. Recent strategic activity includes a February 2026 co-development partnership with SPT Labtech to launch a miniaturized VPS4B ATPase inhibitor screening platform, followed by a May 2026 extension into sirtuin (epigenetic) drug discovery via the Transcreener OAADPr SIRT Assay.
Bellbrook Labs firmographics
Firmographics- Name
- Bellbrook Labs
- Legal name
- BellBrook Labs
- Website
- https://bellbrooklabs.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bellbrook Labs is a privately held Madison, Wisconsin-based biochemical assay company founded in 2005 that develops and sells Transcreener, AptaFluor, Heliscreener, and Enzolution high-throughput screening assay kits, recombinant enzymes, and contract profiling services for enzyme-targeted drug discovery by pharmaceutical, biotech, academic, and CRO customers.
- Ownership category
- akta.pro rank
Bellbrook Labs industry classification
Industry- Product category
- Drug Discovery Biochemical Assay Kits
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Bioanalytical & Biomarker Assays (Preclinical) (HLAGAFAK)
Keywords
Where Bellbrook Labs is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bellbrook Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Assay Kits and Reagents: Sale of biochemical HTS assay kits including Transcreener, AptaFluor, and Heliscreener platforms. Includes kinase assay kits, ATPase assay kits, methyltransferase assay kits, and specialty enzyme assays.
- Recombinant Enzymes: Sale of purified, active human enzymes validated in BellBrook's assays. Products include VPS4A, VPS4B, WRN Helicase, DDX helicases, cGAS, TREX1, PARG, and other disease-relevant enzymes.
- Scientific Services: Fee-for-service assay development, compound testing, dose-response studies, hit validation, and profiling services. Services include Assay Development Services, Lead Discovery Services, ATPase Profiling Services, cGAS/STING Profiling Services, GTPase Profiling Services, Helicase Profiling Services, and Thermal Shift Assay Services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Assay kits and reagents - quote-based pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Bellbrook Labs product offering
Product offeringCore offering
Bellbrook Labs develops, manufactures, and sells biochemical high-throughput screening (HTS) assay kits, recombinant enzymes, assay plates, and small-molecule inhibitors, alongside contract assay development and target profiling services. Its core platforms — Transcreener, AptaFluor, Heliscreener, and Enzolution — enable direct, mix-and-read detection of enzymatic activity for kinase, ATPase, GTPase, phosphodiesterase, glycosyltransferase, exonuclease, methyltransferase, and helicase targets in drug discovery workflows.
Product overview
Bellbrook Labs provides a comprehensive portfolio of biochemical high-throughput screening (HTS) assay solutions for drug discovery. The core offering centers on three proprietary technology platforms: Transcreener (direct nucleotide detection for kinases, ATPases, GTPases, phosphodiesterases, and other nucleotide-consuming enzymes), AptaFluor (SAH methyltransferase detection), and Heliscreener (RNA/DNA helicase unwinding assays). These platforms are complemented by the Enzolution brand of complete assay systems combining validated enzymes, substrates, and protocols. Bellbrook also offers a catalog of HTS-ready recombinant human enzymes and a suite of contract assay development and profiling services. The product architecture enables customers to run proven assays in their own labs or collaborate with Bellbrook scientists for assay validation, hit discovery, and CRO transfer. The company positions its technology as robust, mix-and-read solutions designed for automated HTS environments on common multimode readers.
Differentiator
Problem solved
Functional benefit
Brands
- Transcreener: HTS platform for direct detection of nucleotides produced by nucleotide-dependent enzymatic activity including kinases, ATPases, GTPases, phosphodiesterases, glycosyltransferases, and exonucleases.
- AptaFluor
- Heliscreener
- Enzolution
Products and services
- Transcreener HTS Assays Flagship HTS assay platform for direct detection of nucleotides produced by enzymes, available in fluorescence polarization (FP), fluorescence intensity (FI), and TR-FRET detection modes with continuous or endpoint options. Sold as a family of kits (ADP² kinase, GDP GTPase, pADPr PARP, cGAMP cGAS, OAADPr SIRT, ADPR, ADO CD73, AMP/GMP phosphodiesterase, EPIGEN SAH, dAMP exonuclease, UDP glycosyltransferase, 2-5A OAS) for drug discovery scientists running biochemical HTS campaigns.
- AptaFluor SAH Methyltransferase Assay Kits Mix-and-read assay kits for detecting S-adenosylhomocysteine (SAH) produced by methyltransferases, enabling inhibitor screening against any methyltransferase using SAM at Km concentration. Targeted at epigenetic drug discovery researchers.
- Heliscreener Helicase Unwinding Assay Kits Assay kits for measuring RNA and DNA helicase unwinding activity, including dedicated kits for RNA helicases, BLM (Bloom syndrome protein) helicase, and WRN (Werner syndrome helicase). Sold to drug discovery researchers working on helicase targets.
- Enzolution Assay Systems Bundle product line that packages validated recombinant enzymes, substrates, detection reagents, buffers, and protocols into ready-to-run assay systems for inhibitor discovery against specific enzyme targets. Designed to be used with the Transcreener and AptaFluor detection platforms and sold to HTS and screening groups.
- HTS-Ready Recombinant Enzymes Catalog of purified, active recombinant human enzymes validated for high-throughput screening, sold individually as standalone reagents for customers who want to assemble their own assay workflows with Bellbrook detection reagents. Includes targets such as cGAS, TREX1, PolQ, WRN, PARG, CD38, DDX helicases, MDA5, RIG-I, VPS4A, VPS4B, and more.
- HTS Assay Plates Microplates optimized for use in high-throughput screening workflows with Bellbrook assay kits, sold as a supporting consumable for automated screening platforms.
- Reference Inhibitors Small set of reference small-molecule inhibitors for SMARCA2/4, TBK1, SIRT1, DDX1/DDX41, and PARP1/PARP2 targets, sold as tool compounds for customers running control experiments with Bellbrook assays.
- Assay Development Services Custom assay development service in which Bellbrook scientists establish, troubleshoot, and validate biochemical workflows for customer targets, with the goal of enabling in-house screening, hit confirmation, or transfer to a CRO. Targeted at pharmaceutical and biotech drug discovery teams.
- Lead Discovery Services Compound testing, dose-response studies, hit validation, and profiling services that help customers progress hits from primary screens into qualified lead matter, positioned for AI-driven hit triage workflows. Served to pharmaceutical and biotech discovery teams.
- ATPase Profiling Services Contract profiling service for ATPase enzyme targets using BellBrook's Transcreener ADP2 detection platform, delivered to pharmaceutical and biotech customers for compound screening and characterization.
- cGAS/STING Profiling Services Contract profiling service targeting cGAS and STING pathway enzymes for customers developing innate immunity and oncology drug discovery programs, supported by Bellbrook's Transcreener cGAMP cGAS detection reagents.
- GTPase Profiling Services Contract profiling service for GTPase enzyme targets using Bellbrook's Transcreener GDP GTPase detection chemistry, sold to drug discovery teams screening GTPase inhibitors.
- Helicase Profiling Services
- Thermal Shift Assay Services Thermal shift (DSF) profiling service for measuring compound-target interactions through changes in protein thermal stability, sold to drug discovery teams supporting hit triage and binding characterization.
Quantifiable outcome
- Z' > 0.7 demonstrated in SIRT1 and SIRT2 assays with Transcreener OAADPr assay
- +2 more outcomes
Companies that use Bellbrook Labs
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Bellbrook Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Bellbrook Labs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SPT LabtechcoreCollaboration announced at SLAS 2026 to develop a miniaturized, high-throughput cell-based assay for discovering VPS4B ATPase inhibitors. The platform combines BellBrook Labs' Transcreener ADP2 fluorescence polarization assay with SPT Labtech's dragonfly automated dispensing system, operating in 384- and 1536-well formats. Successfully identified 13 novel VPS4B inhibitors as proof of concept.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Bellbrook Labs competitors and assessment
Company assessmentBroad incumbents
- Bio-Rad Laboratories: Bio-Rad supplies life-science research reagents, antibodies, and assay kits used in drug discovery workflows. Overlaps with BellBrook in biochemical reagents and recombinant proteins but with a much broader catalog.
- Promega Corporation: Promega is a large, diversified life-science tools company offering biochemical and cell-based assay reagents including kinase and ATPase assays. Overlaps with BellBrook's biochemical assay kits but with a much broader product portfolio and global commercial reach.
- Thermo Fisher Scientific: Thermo Fisher offers an extensive life-science reagents catalog including biochemical assay kits, recombinant enzymes, and HTS consumables. Competes broadly across nearly every BellBrook product line as part of a much larger portfolio.
- Revvity (formerly PerkinElmer Life Sciences): Revvity provides HTS detection reagents, plate readers, automation, and screening services across biochemical and cell-based modalities. Competes with BellBrook at the assay-reagent layer while also offering the instrument and software stack BellBrook does not.
- Cisbio / PerkinElmer HTRF (now Revvity): Cisbio's HTRF (Homogeneous Time-Resolved Fluorescence) technology is a widely adopted TR-FRET-based detection platform for HTS. Represents the incumbent alternative to BellBrook's Transcreener FP/TR-FRET assays for kinase and other enzyme targets.
Emerging players
- Enzo Life Sciences: Enzo Life Sciences offers assay kits, recombinant proteins, and biochemical reagents for life-science research with overlap to BellBrook in enzyme and signaling-pathway assays. Smaller and broader-specialty compared to BellBrook's HTS focus.
Regional players
- Charles River Laboratories: Charles River provides discovery and safety assessment services including biochemical assay support for pharma clients. Comparable to BellBrook on the contract profiling services side, though with a much broader non-clinical CRO footprint.
Direct peers
- BPS Biosciences: BPS Biosciences develops recombinant enzymes and biochemical assay kits for drug discovery, including kinase, epigenetic, and immunology targets. Directly comparable to BellBrook's enzyme catalog and biochemical HTS assay portfolio.
- Eurofins DiscoverX: Eurofins DiscoverX provides biochemical and cell-based assay kits, profiling services, and recombinant cell lines for HTS drug discovery. Overlaps with BellBrook in biochemical enzyme assays and contract screening services.
- Reaction Biology Corporation: Reaction Biology offers biochemical profiling services and assay reagents covering kinases, ATPases, and other enzyme targets. Closely matches BellBrook's combined products-and-services business model in biochemical HTS.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bellbrook Labs social profiles
Digital presenceBellbrook Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bellbrook Labs leadership team
Management profileNumber of profiles
Profiles3 records
Bellbrook Labs funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bellbrook Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bellbrook Labs
What does Bellbrook Labs do?
Bellbrook Labs develops, manufactures, and sells biochemical high-throughput screening (HTS) assay kits, recombinant enzymes, assay plates, and small-molecule inhibitors, alongside contract assay development and target profiling services. Its core platforms — Transcreener, AptaFluor, Heliscreener, and Enzolution — enable direct, mix-and-read detection of enzymatic activity for kinase, ATPase, GTPase, phosphodiesterase, glycosyltransferase, exonuclease, methyltransferase, and helicase targets in drug discovery workflows.
Is Bellbrook Labs a public or private company?
Bellbrook Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bellbrook Labs founded?
Bellbrook Labs was founded in 2005. It employs 11 to 50 people.
Where is Bellbrook Labs based?
Bellbrook Labs is headquartered in Madison, United States, in the North America region.
How does Bellbrook Labs make money?
Three revenue lines are on record. Assay Kits and Reagents are the primary driver. The others are recombinant Enzymes and scientific Services.
Who are Bellbrook Labs's main competitors?
Broad incumbents on record are Bio-Rad Laboratories, Promega Corporation, Thermo Fisher Scientific, Revvity (formerly PerkinElmer Life Sciences) and Cisbio / PerkinElmer HTRF (now Revvity). Enzo Life Sciences is listed as an emerging player. Charles River Laboratories is listed as a regional player. Direct peers are BPS Biosciences, Eurofins DiscoverX and Reaction Biology Corporation.
Does Bellbrook Labs have an API?
No public API is recorded for Bellbrook Labs.
What industry is Bellbrook Labs in?
Bellbrook Labs's product category is Drug Discovery Biochemical Assay Kits. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2835.